A. Hasbini

发表

Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial.

A. Ravaud, S. Culine, J. Machiels, 2017, European urology.

Phase II trial of chemotherapy with 5‐fluorouracil, bleomycin, epirubicin, and cisplatin for patients with locally advanced, metastatic, or recurrent undifferentiated carcinoma of the nasopharyngeal type

J. Armand, E. Cvitkovic, N. Chouaki, 1999, Cancer.

Phase II trial combining mitomycin with 5-fluorouracil, epirubicin, and cisplatin in recurrent and metastatic undifferentiated carcinoma of nasopharyngealtype

E. Raymond, J. Armand, E. Cvitkovic, 1999 .

Long survival of patients with metastatic clear cell renal cell carcinoma. Results of real life study of 344 patients

F. Joly, J. Malhaire, E. Voog, 2020, International journal of cancer.

Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design

J. Carles, B. Tombal, F. Calabrò, 2022, The Lancet.

Sequencing of Taxanes and New Androgen-targeted Therapies in Metastatic Castration-resistant Prostate Cancer: Results of the International Multicentre Retrospective CATS Database.

D. Spaeth, S. Oudard, P. Barthélémy, 2018, European urology oncology.

Efficacy of cabazitaxel rechallenge in heavily treated patients with metastatic castration-resistant prostate cancer.

D. Spaeth, S. Oudard, M. Krainer, 2018, European journal of cancer.

Outcome after salvage radiotherapy (brachytherapy +/- external) in patients with a vaginal recurrence from endometrial carcinomas.

C. Haie-meder, A. Gerbaulet, P. Morice, 2002, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Prognostic Factors for Survival in Noncastrate Metastatic Prostate Cancer: Validation of the Glass Model and Development of a Novel Simplified Prognostic Model.

A. Ravaud, J. Machiels, G. Deplanque, 2015, European urology.

Early Toxicity of a Phase 2 Trial of Combined Salvage Radiation Therapy and Hormone Therapy in Oligometastatic Pelvic Node Relapses of Prostate Cancer (OLIGOPELVIS GETUG P07).

F. Denis, D. Pasquier, V. Beckendorf, 2019, International journal of radiation oncology, biology, physics.

[Alternating chemotherapy and hyperfractionated accelerated radiotherapy in non-metastatic inflammatory breast cancer].

L. Zelek, R. Arriagada, J. Habrand, 2000, Cancer Radiothérapie.

Induction Chemotherapy Followed by Cetuximab Radiotherapy Is Not Superior to Concurrent Chemoradiotherapy for Head and Neck Carcinomas: Results of the GORTEC 2007-02 Phase III Randomized Trial.

J. Bourhis, E. Babin, C. Borel, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cabozantinib‐nivolumab sequence in metastatic renal cell carcinoma: The CABIR study

S. Oudard, G. Gravis, N. Houédé, 2022, International journal of cancer.

OLIGOPELVIS GETUG P07, a Multicenter Phase II Trial of Combined High-dose Salvage Radiotherapy and Hormone Therapy in Oligorecurrent Pelvic Node Relapses in Prostate Cancer.

N. Magné, D. Peiffert, F. Denis, 2021, European urology.

Late toxicity and quality of life from GETUG-AFU 22 study.

L. Salomon, S. Guérif, P. Pommier, 2020 .

Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trial.

B. Dubray, S. Guérif, A. Ruffion, 2016, The Lancet. Oncology.

Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial.

A. Ravaud, J. Machiels, B. Esterni, 2013, The Lancet. Oncology.

Oligopelvis-GETUG P07: A multicenter phase II trial of combined salvage radiotherapy and hormone therapy in oligorecurrent pelvic node relapses of prostate cancer.

N. Magné, F. Denis, D. Pasquier, 2020 .

Clinical progression at initiation of a life-extending therapy (LET) in metastatic castration-resistant prostate cancer (mCRPC) is associated with a poor prognosis, whatever the treatment-line: Results of the CATS retrospective registry.

D. Spaeth, S. Oudard, S. Chowdhury, 2019, Journal of Clinical Oncology.

LBA5 A phase III trial with a 2x2 factorial design in men with de novo metastatic castration-sensitive prostate cancer: Overall survival with abiraterone acetate plus prednisone in PEACE-1

B. Tombal, F. Calabrò, S. Foulon, 2021, Annals of Oncology.

A phase 3 trial with a 2x2 factorial design of abiraterone acetate plus prednisone and/or local radiotherapy in men with de novo metastatic castration-sensitive prostate cancer (mCSPC): First results of PEACE-1.

B. Tombal, F. Calabrò, S. Foulon, 2021 .

Clinical progression is associated with poor prognosis whatever the treatment line in metastatic castration resistant prostate cancer: The CATS international database.

D. Spaeth, S. Oudard, P. Barthélémy, 2019, European journal of cancer.

Recommendations for stereotactic body radiation therapy for spine and non-spine bone metastases. A GETUG (French society of urological radiation oncolgists) consensus using a national two-round modified Delphi survey

J. Bibault, J. Faivre, C. Hennequin, 2022, Clinical and translational radiation oncology.

Assessment of tumor angiogenesis as a prognostic factor of survival in patients with oligodendroglioma

C. Lacroix, B. Abdulkarim, H. Quon, 2009, Journal of Neuro-Oncology.

Topotecan preceded by oxaliplatin using a 3 week schedule: a phase I study in advanced cancer patients.

F. Goldwasser, J. Misset, F. Lokiec, 2002, European journal of cancer.

Patterns of practice of androgen deprivation therapy combined to radiotherapy in favorable and unfavorable intermediate risk prostate cancer. Results of The PROACT Survey from the French GETUG Radiation Oncology group.

M. Bolla, S. Guérif, C. Hennequin, 2020, Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique.

Improved Outcome by Adding Concurrent Chemotherapy to Cetuximab and Radiotherapy for Locally Advanced Head and Neck Carcinomas: Results of the GORTEC 2007-01 Phase III Randomized Trial.

J. Bourhis, C. Borel, P. Maingon, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Patients' self-assessment versus investigators' evaluation in a phase III trial in non-castrate metastatic prostate cancer (GETUG-AFU 15).

A. Ravaud, J. Machiels, B. Esterni, 2014, European journal of cancer.

Overall and progression-free survival with cabazitaxel in metastatic castration-resistant prostate cancer in routine clinical practice: the FUJI cohort

A. Fourrier-Réglat, F. Tubach, J. Prevost, 2019, British Journal of Cancer.

Weekly Adaptive Radiotherapy vs Standard Intensity-Modulated Radiotherapy for Improving Salivary Function in Patients With Head and Neck Cancer: A Phase 3 Randomized Clinical Trial.

J. Thariat, J. Castelli, R. de Crevoisier, 2023, JAMA oncology.

Phase II trial combining mitomycin with 5-fluorouracil, epirubicin, and cisplatin in recurrent and metastatic undifferentiated carcinoma of nasopharyngeal type.

E. Raymond, J. Armand, E. Cvitkovic, 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

Randomized phase II trial in prostate cancer with hormone-sensitive OligometaSTatic relapse: Combining stereotactic ablative radiotherapy and durvalumab (POSTCARD GETUG P13): Study protocol

F. Denis, U. Schick, P. Pommier, 2023, Clinical and translational radiation oncology.

A Randomized, Open-label, Cross-over Phase 2 Trial of Darolutamide and Enzalutamide in Men with Asymptomatic or Mildly Symptomatic Metastatic Castrate-resistant Prostate Cancer: Patient Preference and Cognitive Function in ODENZA.

S. Foulon, S. Ladoire, Y. Neuzillet, 2023, European urology.

[Ductal carcinoma in situ: role of the boost].

I. Barillot, P. Maingon, A. Monnier, 2008, Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique.

1361MO 8-month PSA strongly predicts outcomes of men with metastatic castration-sensitive prostate cancer in the PEACE-1 phase III trial

J. McCaffrey, F. Calabrò, A. Thiery-Vuillemin, 2022, Annals of Oncology.

1363MO Cabazitaxel every 2 weeks versus every 3 weeks in older patients with metastatic castration-resistant prostate cancer (mCRPC): The CABASTY randomized phase III trial

S. Oudard, N. Houédé, D. Pfister, 2022, Annals of Oncology.

Improved Outcome by Adding Concurrent Chemotherapy to Cetuximab and Radiotherapy for Locally Advanced Head and Neck Carcinomas: Results of the GORTEC 2007-01 Phase III Randomized Trial.

J. Bourhis, C. Borel, P. Maingon, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Biweekly vs Triweekly Cabazitaxel in Older Patients With Metastatic Castration-Resistant Prostate Cancer: The CABASTY Phase 3 Randomized Clinical Trial.

A. Thiery-Vuillemin, E. Voog, C. Helissey, 2023, JAMA oncology.

Pain and Health-related Quality of Life with Biweekly Versus Triweekly Cabazitaxel Schedule in Older Men with Metastatic Castration-resistant Prostate Cancer in the Multicenter, Randomized CABASTY Trial.

A. Thiery-Vuillemin, E. Voog, C. Helissey, 2024, European urology oncology.